Changes in female cancer diagnostic billing rates over the COVID-19 period in the Ontario Health Insurance Plan
The expected female cancer billing rate decreases in 2020 were followed by large increases in 2021 and 2022, resulting in a cumulative excess during the COVID-19 period. Further research is required to assess the nature of these changes.
Authors
- Christine Brezden‐Masley (ORCID: https://orcid.org/0000-0002-4818-318X)
- Ilidio Martins (ORCID: https://orcid.org/0000-0002-7966-7478)
- Alon D. Altman
- Nathalie LeVasseur (ORCID: https://orcid.org/0000-0002-2581-4903)
- Anna V. Tinker (ORCID: https://orcid.org/0000-0002-1190-7746)
- Amanda Selk (ORCID: https://orcid.org/0000-0003-3744-8258)
- Deanna McLeod (ORCID: https://orcid.org/0000-0003-2206-3726)
Institutions
- BC Cancer Agency (CA)
- Mount Sinai Hospital (CA)
- University of British Columbia (CA)
- University of Toronto (CA)
- Women's College Hospital (CA)
- CancerCare Manitoba (CA)
- Sinai Health System (CA)
- University of Manitoba (CA)
Publication Details
- Journal
- Therapeutic Advances in Medical Oncology
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1177/17588359251339919
- Primary Topic
- COVID-19 and healthcare impacts
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Eisai Canada